1. Introduction {#sec1-nutrients-09-00858}
===============

Vascular calcification is observed in arteriosclerosis and reduces aortic and arterial elastance. Intimal calcification is commonly associated with atherosclerosis. Medial calcification is often observed in patients with type 2 diabetes mellitus and end-stage renal disease, and is known as Mönckeberg's medial sclerosis (MMS). This type of calcification leads to systolic hypertension and fluctuation of blood pressure, finally causing cardiac hypertrophy, myocardial ischemia, peripheral arterial ischemia, and congestive heart failure \[[@B1-nutrients-09-00858],[@B2-nutrients-09-00858],[@B3-nutrients-09-00858],[@B4-nutrients-09-00858],[@B5-nutrients-09-00858]\].

Eicosapentaenoic acid (EPA) is effective for the prevention and treatment of arteriosclerotic diseases \[[@B6-nutrients-09-00858],[@B7-nutrients-09-00858],[@B8-nutrients-09-00858],[@B9-nutrients-09-00858]\]. EPA has also suppressed vascular calcification in animal experiments \[[@B10-nutrients-09-00858],[@B11-nutrients-09-00858],[@B12-nutrients-09-00858],[@B13-nutrients-09-00858],[@B14-nutrients-09-00858]\]. Since EPA has multiple physiological activities, it is important to clarify the specific mechanism by which vascular calcification is suppressed.

The Wnt signaling pathway is involved in various aging phenotypes, including vascular calcification \[[@B15-nutrients-09-00858],[@B16-nutrients-09-00858],[@B17-nutrients-09-00858],[@B18-nutrients-09-00858],[@B19-nutrients-09-00858],[@B20-nutrients-09-00858],[@B21-nutrients-09-00858],[@B22-nutrients-09-00858]\]. Patients with chronic kidney disease (CKD) show significant arterial calcification, and have a very high risk of developing cardiovascular diseases \[[@B23-nutrients-09-00858],[@B24-nutrients-09-00858]\]. They also have mineral and bone disorders, and high phosphate induces vascular calcification through activating Wnt/β-catenin signaling \[[@B25-nutrients-09-00858]\]. *Klotho* mutant (*kl*/*kl*) mice show severe tissue calcium deposition, including vascular medial calcification \[[@B21-nutrients-09-00858]\]. Since Klotho binds to multiple Wnt ligands and inhibits Wnt signaling activation, Wnt signaling is activated in *kl*/*kl* mice \[[@B22-nutrients-09-00858],[@B26-nutrients-09-00858]\]. Klotho is mainly produced in the kidneys, and the secreted form is released into the blood \[[@B27-nutrients-09-00858],[@B28-nutrients-09-00858]\]. Reduced production of klo tho is also observed in Patients with CKD \[[@B25-nutrients-09-00858]\].

Since we have observed a remarkable suppressive effect of EPA on arterial calcification of *kl*/*kl* mice \[[@B12-nutrients-09-00858]\], we investigated the effect of EPA on Wnt signaling in arterial calcification. We first examined whether EPA can upregulate *Klotho* expression in the kidney. Meanwhile, the intake of powder chow supplemented with 5% purified EPA significantly suppressed vascular calcification in *kl*/*kl* mice, despite a defect of Klotho production \[[@B12-nutrients-09-00858]\]. Additionally, whether Klotho is expressed in the artery is controversial \[[@B29-nutrients-09-00858],[@B30-nutrients-09-00858],[@B31-nutrients-09-00858]\]. Thus, we consequently investigated the effects of EPA on Wnt signaling in vascular smooth muscle cells (VSMCs).

2. Materials and Methods {#sec2-nutrients-09-00858}
========================

2.1. Animal Experiment {#sec2dot1-nutrients-09-00858}
----------------------

*Klotho mutant* (*kl*/*kl*) mice were purchased from Clea Japan (Tokyo, Japan). Four-week-old *kl*/*kl* mice and wild-type mice were given diets either containing 5% EPA (Mochida Pharmaceutical Co., Ltd., Tokyo, Japan) (EPA diet), or not containing EPA (control diet), for four weeks. All animal protocols were approved and conducted according to the recommendations of Okayama University on Animal Care and Use. The animal procedures performed conform to the National Institutes of Health (NIH) guidelines (Guide for the Care and Use of Laboratory Animals).

2.2. Immunohistochemical Staining {#sec2dot2-nutrients-09-00858}
---------------------------------

Mice were anesthetized by intraperitoneal injection of 40 mg/kg pentobarbital (Kyoritsu Seiyaku Corporation, Tokyo, Japan). Then, thoracotomy was performed, and the mice were transcardially perfused with saline. The aorta and kidney of each mouse were harvested under a stereoscopic microscope (SZ61, Olympus, Tokyo, Japan). The aorta was embedded in Optimal Cutting Temperature Compound (Sakura Fintek, Tokyo, Japan). The embedded tissues were sectioned at 5 μm in a microtome (CM1850, Leica, Wetzlar, Germany) and mounted on slide glasses (S-0317, Matsunami Glass, Osaka, Japan). They were fixed in 4% paraformaldehyde for 15 min, followed by incubation with Blocking One Histo (Nacalai Tesque, Kyoto, Japan) for 30 min, and then they were stained with primary antibodies against β-catenin (1:100 dilution, D10A8 XP, Cell Signaling Technology, Danvers, MA, USA) and α-SMA (1:400 dilution, Clone 1A4, Sigma Aldrich, St. Louis, MO, USA). The secondary antibodies used were tetramethylrhodamine (TRITC) swine anti-rabbit Ig (1:20, Dako, Santa Clara, CA, USA), and Alexa Fluor 488 goat anti-mouse IgG (1:200, Molecular Probes, Eugene, OR, USA).

2.3. Cell Culture {#sec2dot3-nutrients-09-00858}
-----------------

Primary human aortic smooth muscle cells (HAoSMCs) purchased from Lonza (Basel, Switzerland) were cultured in Smooth Muscle Growth Medium-2 (SmGM-2, Lonza). Cells between passages 5--9 were used for all experiments. In loading experiments, cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 0.5% fetal bovine serum (HyClone, South Logan, UT, USA), and some reagents and were harvested after 48 h. EPA (Sigma Aldrich) was dissolved in ethanol. One hundred ng/mL Wnt3a (R&D Systems, Minneapolis, MN, USA), 1 μg/mL heparin (Sigma Aldrich), 1 μmol/L 6-bromoindirubin-3′-oxime (BIO) (Wako, Osaka, Japan), and/or 10 μmol/L T0070907 (Tocris Bioscience, Bristol, UK) were used in cell culture experiments.

2.4. Cell Staining {#sec2dot4-nutrients-09-00858}
------------------

HAoSMCs were plated on 0.1% gelatin-coated cover glasses, and fixed in 4% paraformaldehyde. The cells were stained with rhodamine-phalloidin (1:200 dilution, Molecular Probes, Eugene, OR, USA) and Hoechst 33342 (1:5000 dilution, Molecular Probes). Rhodamine-phalloidin is an F-actin probe conjugated to the red-orange fluorescent dye, tetramethylrhodamine. Hoechst 33342 is a blue dye for cell fluorescence of nuclei.

2.5. Quantitative PCR {#sec2dot5-nutrients-09-00858}
---------------------

Murine kidneys in Trizol Reagent were homogenized using Bead Crusher μT-01 (Taitec, Saitama, Japan). HAoSMCs were also lysed using Trizol Reagent. Total RNA was extracted using a Trizol Plus RNA Purification Kit (Invitrogen, Carlsbad, CA, USA). Complementary DNA was synthesized from less than 1 μg of total RNA using a SuperScript VILO cDNA Synthesis Kit (Invitrogen), as prescribed in the manual and subjected to PCR amplification. Taq DNA polymerase (Takara, Shiga, Japan) was used for reverse transcription-polymerase chain reaction (RT-PCR), and PCR products were subjected to electrophoresis in 2% agarose gels and stained with ethidium bromide. KAPA SYBR Fast qPCR Kit (Kapa Biosystems, Wilmington, MA, USA) and Applied Biosystems 7300 Real-Time PCR Systems (Applied Biosystems, Foster City, CA, USA) were used for quantitative PCR (*q*-PCR). The *q*-PCR data were processed by a *ΔΔ*CT method. PCR primers are shown in [Table 1](#nutrients-09-00858-t001){ref-type="table"}. The *q*-PCR experiments were performed in triplicate four times.

2.6. FFAR4 Knockdown by siRNA {#sec2dot6-nutrients-09-00858}
-----------------------------

To knockdown *FFAR4* in HAoSMCs, 5 μmol/L small interfering RNA (siRNA, s200889, Ambion, Foster City, CA, USA) was transfected using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions. *FFAR4* downregulation was confirmed by RT-PCR.

2.7. Statistical Analysis {#sec2dot7-nutrients-09-00858}
-------------------------

All data are expressed as means ± SE. Statistical analysis was performed by Student's *t* test for unpaired data or one-way ANOVA, with comparison of different groups by Tukey's post hoc test using SPSS statistics 24 (IBM, Armonk, NY, USA). Values of *p* \< 0.05 were considered to be significant.

3. Results {#sec3-nutrients-09-00858}
==========

3.1. Intake of EPA Food Upregulated Klotho Expression in Kidneys of Wild-Type Mice {#sec3dot1-nutrients-09-00858}
----------------------------------------------------------------------------------

*Klotho* mRNA levels in mice fed the EPA diet (*n* = 8) were about 1.5 times higher than the levels in mice fed the control diet (*n* = 4) ([Figure 1](#nutrients-09-00858-f001){ref-type="fig"}A). In *kl*/*kl* mice, the intake of EPA did not change serum phosphate, and did not increase *Klotho* expression (control diet, *n* = 2; EPA diet, *n* = 2) ([Figure 1](#nutrients-09-00858-f001){ref-type="fig"}B) \[[@B12-nutrients-09-00858]\]. Expression of the nuclear receptor and plasma membrane receptor of EPA, PPARγ and FFAR4, respectively, were confirmed by RT-PCR ([Figure 1](#nutrients-09-00858-f001){ref-type="fig"}C).

3.2. Beta-Catenin Expression Increased in the Aortas of Kl/kl Mice {#sec3dot2-nutrients-09-00858}
------------------------------------------------------------------

The medial layer, which was α-SMA positive, showed hyperplasia, while the expression of β-catenin, an intracellular signal transducer in the Wnt signaling pathway, was detected in more sections of aortas from *kl*/*kl* mice (control diet, number of animals = 2 and number of tissue sections = 7; EPA diet, number of animals = 2 and number of tissue sections = 6) than in sections of aortas from wild-type mice (control diet, number of animals = 2 and number of tissue sections = 6; EPA diet, number of animals = 2 and number of tissue sections = 7) ([Figure 2](#nutrients-09-00858-f002){ref-type="fig"}A,B).

3.3. EPA Suppressed the Expression of Wnt Signaling Marker and Early Osteogenic Genes {#sec3dot3-nutrients-09-00858}
-------------------------------------------------------------------------------------

Wnt3a (100 ng/mL) increased not only the expression of Wnt signaling marker genes *AXIN2* and *LEF1*, but also the expression of *RUNX2* and *BMP4*, which are genes associated with vascular calcification \[[@B20-nutrients-09-00858],[@B32-nutrients-09-00858],[@B33-nutrients-09-00858],[@B34-nutrients-09-00858],[@B35-nutrients-09-00858]\]. Upregulation of these genes was suppressed by 25 μmol/L EPA ([Figure 3](#nutrients-09-00858-f003){ref-type="fig"}A). EPA did not completely suppress the upregulation genes by Wnt3a at 10 μmol/L, and 100 μmol/L EPA induced cell death ([Figure 3](#nutrients-09-00858-f003){ref-type="fig"}B). We therefore used 25 μmol/L EPA in subsequent experiments.

3.4. EPA Suppressed β-Catenin Signaling via PPARγ Activation {#sec3dot4-nutrients-09-00858}
------------------------------------------------------------

BIO (1 μmol/L), a GSK-3 inhibitor that activates β-catenin signaling, also increased the expression of *AXIN2*, *LEF1*, *RUNX2* and *BMP4*. Upregulation of *AXIN2* and *BMP4* was significantly suppressed, and *RUNX2* tended to be suppressed by 25 μmol/L EPA. EPA is known as a PPARγ agonist and also increased *PPARG* expression. The effects of EPA were cancelled by 10 μmol/L T0070907, a PPARγ inhibitor ([Figure 4](#nutrients-09-00858-f004){ref-type="fig"}A). Additionally, BIO made actin fibers sparse, and EPA modestly mitigated the morphological change. The expression of *MYH11*, a mature contractile smooth muscle cell marker, was decreased by BIO, and the expression was recovered by EPA. T0070907 cancelled the effect of EPA ([Figure 4](#nutrients-09-00858-f004){ref-type="fig"}A,B). The knockdown of *FFAR4*, a receptor of ω-3 fatty acids, did not cancel the inhibitory effect of EPA on *AXIN2* and *LEF1* expression ([Figure 5](#nutrients-09-00858-f005){ref-type="fig"}A,B) \[[@B36-nutrients-09-00858]\].

4. Discussion {#sec4-nutrients-09-00858}
=============

Our study revealed that EPA upregulated the expression of *Klotho*, a Wnt signaling inhibitor, in the kidney and inhibited Wnt signaling in osteogenic VSMCs via PPARγ, as shown in [Figure 6](#nutrients-09-00858-f006){ref-type="fig"}. These results suggested that the effects could lead to the suppression of vascular calcification. In addition to our previous study, the results of the present study using human VSMCs suggested that EPA can also affect human vascular calcification by the suppression of Wnt signaling \[[@B12-nutrients-09-00858]\]. This study is therefore a step toward the pathology of arteriosclerosis.

The intake of EPA increased *Klotho* mRNA expression in the kidney, as shown in [Figure 1](#nutrients-09-00858-f001){ref-type="fig"}. Klotho inhibits the binding of Wnt ligands to their receptors \[[@B26-nutrients-09-00858]\]. The upregulated expression of Klotho in the kidney is presumed to suppress vascular calcification; however, we did not examine how EPA upregulated Klotho expression. Meanwhile, PPARγ activation has been reported to be one of the methods for increasing Klotho production in the kidney, because the *Klotho* gene has a PPAR-responsive element (PPRE) \[[@B25-nutrients-09-00858],[@B37-nutrients-09-00858]\]. Additionally, EPA can directly activate PPARγ \[[@B38-nutrients-09-00858]\]. The upregulation of expression by EPA that was observed in our study is a compatible result. However, wild-type mice were used in this study to examine *Klotho* expression in the kidneys. Thus, it is unclear whether EPA increases Klotho production in a pathological situation. Further investigation using other pathological model animals without a Klotho defect is therefore required.

We previously reported that intake of an EPA diet also significantly suppressed vascular calcification in *kl*/*kl* mice, despite a defect of Klotho production \[[@B12-nutrients-09-00858]\]. Furthermore, it is not clear whether vascular Klotho is expressed endogenously \[[@B29-nutrients-09-00858],[@B30-nutrients-09-00858],[@B31-nutrients-09-00858]\]. Thus, we consequently investigated the direct effects of EPA on Wnt signaling in the aorta. Increased β-catenin expression in the aortas of *kl*/*kl* mice, as shown in [Figure 2](#nutrients-09-00858-f002){ref-type="fig"}, suggested an enhancement of Wnt/β-catenin signaling in the calcified aorta.

Vascular calcification in the tunica media observed in *kl*/*kl* mice and CKD patients is a characteristic manifestation \[[@B21-nutrients-09-00858],[@B39-nutrients-09-00858]\]. We therefore investigated the effect of EPA in VSMCs, which are a component of the tunica media. We revealed that the enhancement of Wnt/β-catenin signaling by a Wnt ligand or a GSK-3 β inhibitor resulted in osteogenic changes of human VSMCs, as previous studies have demonstrated \[[@B18-nutrients-09-00858],[@B19-nutrients-09-00858],[@B20-nutrients-09-00858],[@B34-nutrients-09-00858],[@B40-nutrients-09-00858]\]. Furthermore, EPA suppressed the changes, as shown in [Figure 3](#nutrients-09-00858-f003){ref-type="fig"} and [Figure 4](#nutrients-09-00858-f004){ref-type="fig"}. EPA has also been reported to prevent palmitic acid-induced osteoblastic changes in VSMCs \[[@B41-nutrients-09-00858]\]. The mechanisms by which EPA suppresses vascular calcification have been reported to be a reduction of matrix metalloproteinase production, and a reduction of oxidative stress \[[@B11-nutrients-09-00858],[@B12-nutrients-09-00858]\]. It has been shown that ω-3 fatty acids are known to suppress Wnt signaling in various types of cancer cells \[[@B42-nutrients-09-00858],[@B43-nutrients-09-00858],[@B44-nutrients-09-00858]\]. Thus, our results, shown in [Figure 4](#nutrients-09-00858-f004){ref-type="fig"}, suggested that similar mechanisms might act in osteogenic VSMCs via activation of PPARγ.

We previously reported that FFAR4 signaling is responsible for decreasing oxidative stress in mice \[[@B12-nutrients-09-00858]\]; however, FFAR4 was not associated with the inhibitory effects of EPA on Wnt signaling in this experimental situation, as shown in [Figure 5](#nutrients-09-00858-f005){ref-type="fig"}. These results suggested that FFAR4 signaling might suppress vascular calcification by other mechanisms.

It is not known whether a decrease in coronary calcification reduces cardiovascular events. Vascular calcification seems to prevent the rupture of vulnerable plaques, because a statin could increase vascular calcification, despite the reduction of cardiovascular events \[[@B45-nutrients-09-00858],[@B46-nutrients-09-00858]\]. Evaluation using optical coherence tomography and intravascular ultrasound demonstrated that adding on EPA to statin did not change calcified plaque volume; however, it did stabilize the plaques of human coronary arteries \[[@B47-nutrients-09-00858],[@B48-nutrients-09-00858]\]. Our study revealed that EPA suppresses Wnt signaling in smooth muscle cells. EPA is also known to affect macrophages and endothelial cells \[[@B49-nutrients-09-00858],[@B50-nutrients-09-00858],[@B51-nutrients-09-00858]\]. Additionally, Wnt signaling is associated with inflammation and aging \[[@B52-nutrients-09-00858],[@B53-nutrients-09-00858]\]. EPA therefore seems to affect not only vascular calcificationm but also other arteriosclerotic processes via the modulation of Wnt signaling \[[@B54-nutrients-09-00858]\].

Since the amount of intake of EPA in this study is extremely large for humans, we should look for a specific target for clinical implication. EPA is converted to metabolites with various physiological activities in vivo \[[@B55-nutrients-09-00858],[@B56-nutrients-09-00858],[@B57-nutrients-09-00858],[@B58-nutrients-09-00858]\]. We did not examine metabolites in this study because it is difficult to understand the effects of metabolites produced by cells other than VSMCs, e.g., endothelial cells, in an in vitro study \[[@B59-nutrients-09-00858]\]. Thus, analyses of metabolites in each tissue or organ might be useful to gain a deeper understanding of the effects of EPA on vascular calcification.

In conclusion, this study revealed that EPA increased the expression of Klotho, an inhibitor of Wnt signaling, in the kidney, and inhibited osteogenic change via enhancement of Wnt signaling in VSMCs. These effects of EPA might lead to suppression of vascular calcification.
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![*Klotho* (*kl*/*kl*) mRNA expression levels in kidneys of mice. (**A**) *Klotho* mRNA expression levels in kidneys of wild-type mice fed a diet with or without eicosapentaenoic acid (EPA). Data are shown as means ± SE (Control diet, *n* = 4; EPA diet, *n* = 8) and were analyzed using Student's *t* test; (**B**) *Klotho* mRNA expression levels in kidneys of *kl*/*kl* mice fed a diet with or without EPA. Data are shown as means (*n* = 2 in each group); (**C**) Reverse transcription-polymerase chain reaction (RT-PCR) showed the mRNA of EPA receptors, *Pparg* and *Ffar4*, in the kidney.](nutrients-09-00858-g001){#nutrients-09-00858-f001}

![Beta-catenin expression in aortas of mice. (**A**) Immunostaining of mouse aortas: green, α-smooth muscle actin (α-SMA); red, β-catenin; and blue, DNA; (**B**) Proportions of β-catenin-positive aorta sections (total numbers of sections: Wild-type (WT) mice fed control diet, *n* = 7; WT mice fed EPA diet, *n* = 6; *kl*/*kl* mice fed control diet, *n* = 6; and *kl*/*kl* mice fed EPA diet, *n* = 7). Bar = 100 μm.](nutrients-09-00858-g002){#nutrients-09-00858-f002}

![Effects of Wnt3a and EPA on human aortic smooth muscle cells (HAoSMCs). (**A**) Changes of the gene expression pattern in HAoSMCs treated with or not treated with 100 ng/mL Wnt3a and/or EPA. Data are shown as means ± SE (*n* = 4 in each group), and were analyzed using one-way ANOVA with Tukey's post hoc test. EtOH means ethanol; (**B**) Cytotoxicity of EPA in HAoSMCs. Bar = 100 μm.](nutrients-09-00858-g003){#nutrients-09-00858-f003}

![Effects of EPA on β-catenin signaling stimulated by GSK-3 inhibitor. (**A**) Changes of the gene expression pattern in HAoSMCs treated with 1 μmol/L BIO, with or without EPA/T0070907. Data are shown as means ± SE (*n* = 4 in each group) and were analyzed using one-way ANOVA with Tukey's post hoc test. T means T0070907 (10 μmol/L); (**B**) Morphological changes of HAoSMCs. Red and blue represent *f*-actin and DNA, respectively. Bar = 100 μm.](nutrients-09-00858-g004){#nutrients-09-00858-f004}

![Effect of the knockdown of *FFAR4* on Wnt signaling in HAoSMCs. (**A**) The knockdown of *FFAR4* in HAoSMCs was confirmed by RT-PCR; (**B**) The effect of knockdown of *FFAR4* on the expression of *AXIN2* and *LEF1*, downstream genes of Wnt signaling. Data are shown as means ± SE (*n* = 3 in each group) and were analyzed using one-way ANOVA with Tukey's post hoc test.](nutrients-09-00858-g005){#nutrients-09-00858-f005}

![Mechanisms by which EPA suppresses vascular calcification via inhibition of Wnt signaling.](nutrients-09-00858-g006){#nutrients-09-00858-f006}

nutrients-09-00858-t001_Table 1

###### 

PCR primer pairs.

                                           Sequence                  Annealing Temperature (°C)   Product Size (bp)
  ---------- ----------------------------- ------------------------- ---------------------------- -------------------
  Mouse                                                                                           
  *Klotho*   forward                       CAAAGTCTTCGGCCTTGTTC      60                           111
  reverse    CTCCCCAAGCAAAGTCACA                                                                  
  *Pparg*    forward                       ATCATCTACACGATGCTGGCC     60                           81
  reverse    CTCCCTGGTCATGAATCCTTG                                                                
  *Ffar4*    forward                       TGCCCCTCTGCATCTTGTTC      60                           202
  reverse    CGCGATGCTTTCGTGATCTG                                                                 
  *Actb*     forward                       GGAGGGGGTTGAGGTGTT        60                           70
  reverse    GTGTGCACTTTTATTGGTCTCAA                                                              
  Human                                                                                           
  *AXIN2*    forward                       AGTGTGAGGTCCACGGAAAC      58                           103
  reverse    CTGGTGCAAAGACATAGCCA                                                                 
  *LEF1*     forward                       AATGAGAGCGAATGTCGTTGC     60                           137
  reverse    GCTGTCTTTCTTTCCGTGCTA                                                                
  *RUNX2*    forward                       TCTTAGAACAAATTCTGCCCTTT   58                           136
  reverse    TGCTTTGGTCTTGAAATCACA                                                                
  *BMP4*     forward                       GATCCACAGCACTGGTCTTG      60                           150
  reverse    GGGATGCTGCTGAGGTTAAA                                                                 
  *PPARG*    forward                       GGCTTCATGACAAGGGAGTTTC    60                           74
  reverse    AACTCAAACTTGGGCTCCATAAAG                                                             
  *MYH11*    forward                       AGATGGTTCTGAGGAGGAAACG    60                           85
  reverse    AAAACTGTAGAAAGTTGCTTATTCACT                                                          
  *FFAR4*    forward                       CTGTGCAGGAATGAGTGGAAG     60                           197
  reverse    CTGATGGAGGGTACTGGAAATG                                                               
  *GAPDH*    forward                       GCGAGATCCCTCCAAAATCAA     58                           172
  reverse    GTTCACACCCATGACGAACAT                                                                
